• In the 28 years since its IPO to December 31st 2025, Eurofins has delivered a remarkable total shareholder return (reflecting both share price appreciation and reinvestment of dividends) of around 38,300%, which is equivalent to a compounded annual growth rate (CAGR) of over 23%.

• Among all companies with listings in major European exchanges over the 1997-2022 period analysed by a research firm, Eurofins ranked highest in terms of total shareholder return.

Read more in Eurofins: 25 Years of Shareholder Value Creation

• Eurofins is a leading provider of analytical testing services, with a large majority of Eurofins' revenues coming from markets where the Group has established global leadership positions. Our areas of activity span Life, BioPharma, Diagnostic Services & Products, and Consumer & Technology Products Testing. 

• Long‑term market growth above GDP is underpinned by strong secular fundamentals. These include the increasing outsourcing of laboratory activities; rising global demand for safe pharmaceuticals, quality food and a clean environment; supportive global trends in regulation; and the consolidation of a highly fragmented testing market.

• Eurofins has been one of the fastest growing listed European companies. Since its IPO on the Paris stock exchange in 1997, Eurofins’ revenues have increased by 31% each year (in compound average) to reach €7.296 billion in 2025.

Read more in Eurofins' corporate presentation

• A one-of-a-kind "hub and spoke" laboratory network infrastructure is our platform for market leadership. Local spoke laboratories address immediate local testing needs, and hub competence centres concentrate on more specialised testing demands to facilitate greater volume and better efficiency, connected by state-of-the-art IT solutions and integrated logistics.

• Eurofins' network brings significant competitive advantages. These include being a one-stop-shop fulfilling the broadest range of customer requirements; economies of scale providing large cost advantages; standardisation of the test portfolio and processes where needed; fast go-to-market as new tests can be quickly rolled out across the network; and providing a platform for integrating acquired business.

Read more in Eurofins' corporate presentation

• Eurofins is in the advanced stages of a five-year programme of investments to continue the build-out of our best-in-class hub and spoke laboratory network, roll out key IT projects including suites of bespoke state-of-the art solutions by business line, establish ownership of strategic sites, and continue the multi-year programme of establishing start-up laboratories.
  
  
• Complete North America networks are already driving leverage through consolidation of laboratories and lower cost of growth; and start-up laboratories from the peak initiation years of 2022-23 became profitable in aggregate in 2025. 
  
  
• The benefits of the hub and spoke network and maturing start-up investments should continue to accumulate, and as we move through 2026-27, the completion of projects to fully digitalise the laboratory network will enable further productivity gains, including material savings in IT costs.

Read more in Eurofins' most recent financial announcements

• Long-term average growth objective of 6.5% per annum, as well as a target of potential average revenues from acquisitions of €250m per annum over the period consolidated at mid-year.
  
  
• Adjusted EBITDA margin on total revenues objective for FY 2027 remains 24%, with the objective for SDI at the EBITDA level about 0.5% of revenues; and further increases in Free Cash Flow to the Firm and ROCE are expected, with the objective for cash conversion in FY 2027 remaining above 50%.
  
  
• From 2028, Eurofins will benefit from a well invested, uniquely efficient and digital hub and spoke laboratories platform, to drive unique levels of service to clients and associated profit and cash flow growth for many years.

More detail on Eurofins' objectives, and definitions of Alternative Performance Measures, can be found in the most recent Full and Half Year results announcements